Full text is available at the source.
Suvorexant for the treatment of sleep disorders in children with severe cerebral palsy
Suvorexant for treating sleep problems in children with severe cerebral palsy
AI simplified
Abstract
Suvorexant was effective in 81% of patients with sleep disorders among children with severe cerebral palsy.
- Sixteen patients aged 2-16 with sleep disorders were treated with suvorexant.
- Efficacy rates varied by sleep disturbance type, with 100% effectiveness for early awakening disorders.
- The mean maintenance dose in effective cases was 0.3 mg/kg.
- Significant reductions in insomnia scores were observed, decreasing from a mean of 15.0 to 4.7.
- No major adverse events were reported during the study.
AI simplified